ProfileGDS5678 / 1434253_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 71% 71% 76% 71% 72% 72% 79% 76% 71% 69% 71% 69% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3866670
GSM967853U87-EV human glioblastoma xenograft - Control 24.5157171
GSM967854U87-EV human glioblastoma xenograft - Control 34.5141571
GSM967855U87-EV human glioblastoma xenograft - Control 45.1852876
GSM967856U87-EV human glioblastoma xenograft - Control 54.5067971
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5575872
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5181572
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4366779
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1808276
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.5087771
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2673369
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4932171
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2582469
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2570969